Nan Fung Trinity HK Ltd. Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Nan Fung Trinity HK Ltd. acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 938,200 shares of the biotechnology company’s stock, valued at approximately $7,815,000. Nan Fung Trinity HK Ltd. owned approximately 0.37% of BioCryst Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. NewEdge Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 4.6% during the 1st quarter. NewEdge Advisors LLC now owns 52,326 shares of the biotechnology company’s stock valued at $498,000 after purchasing an additional 2,285 shares in the last quarter. Kestra Advisory Services LLC raised its stake in BioCryst Pharmaceuticals by 20.5% in the first quarter. Kestra Advisory Services LLC now owns 15,740 shares of the biotechnology company’s stock worth $150,000 after buying an additional 2,680 shares in the last quarter. Nykredit A S bought a new position in BioCryst Pharmaceuticals in the second quarter worth about $27,000. Northwestern Mutual Wealth Management Co. boosted its position in BioCryst Pharmaceuticals by 40.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 10,254 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 2,942 shares in the last quarter. Finally, Winthrop Capital Management LLC bought a new stake in BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $25,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $7.68 on Friday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.23 and a 1 year high of $11.22. The firm has a 50-day moving average of $8.28 and a 200 day moving average of $8.77. The stock has a market cap of $1.98 billion, a P/E ratio of -5.41 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative net margin of 37.40% and a negative return on equity of 92.91%. The business had revenue of $180.29 million for the quarter, compared to analysts’ expectations of $165.67 million. During the same quarter in the prior year, the company earned $0.06 earnings per share. The business’s revenue was up 13.1% compared to the same quarter last year. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on BCRX shares. Weiss Ratings downgraded BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. JPMorgan Chase & Co. raised their target price on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Royal Bank Of Canada cut BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $13.00 to $11.00 in a research note on Thursday, September 10th. Finally, Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 7th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.38.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.